Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity

Inclusion criteria

• Ability to understand and the willingness to sign a written informed consent.
• 18-75 year old patients with newly-diagnosed cancer scheduled to undergo anthracycline-based chemotherapy (minimum of 200 mg/m2 of doxorubicin or equivalent) at UCSD Medical Center.
• Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Women of child-bearing potential must have a negative pregnancy test during the screening period.

Exclusion criteria

• Prior chemotherapy with anthracycline;
• Persistent tachycardia (heart rate>90);
• LVEF<53% or history of cardiomyopathy or decompensated heart failure;
• Baseline GLS below lower limit of normal (normal range varies depending on age and gender (23)) or inability to obtain meaningful strain data due to poor quality of Echocardiographic images;
• Known unrevascularized coronary artery disease, myocardial infarction within 30 days of enrollment;
• Moderate or severe valvular heart disease;
• Prior allergy or intolerance to iodinated contrast;
• Renal failure (GFR<30, creatinine >1.5);
• Cancer involvement of the heart.